Last reviewed · How we verify
Autologous transplantation using Bexxar/BEAM
Bexxar/BEAM is a high-dose chemotherapy regimen (BEAM: carmustine, etoposide, cytarabine, melphalan) followed by autologous stem cell transplantation to treat lymphomas by delivering intensive chemotherapy and restoring bone marrow function.
Bexxar/BEAM is a high-dose chemotherapy regimen (BEAM: carmustine, etoposide, cytarabine, melphalan) followed by autologous stem cell transplantation to treat lymphomas by delivering intensive chemotherapy and restoring bone marrow function. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma, Hodgkin lymphoma (as conditioning for autologous transplantation).
At a glance
| Generic name | Autologous transplantation using Bexxar/BEAM |
|---|---|
| Also known as | Tositumomab and Iodine I 131 Tositumomab Bexxar |
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Chemotherapy regimen with autologous stem cell transplantation |
| Target | CD20 (if Bexxar component); non-specific cytotoxic chemotherapy (BEAM) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BEAM is a myeloablative conditioning regimen that delivers high-dose chemotherapy to eliminate malignant lymphoma cells. Following chemotherapy, autologous hematopoietic stem cells (previously harvested from the patient) are reinfused to restore bone marrow function and immune recovery. Bexxar (tositumomab, an anti-CD20 monoclonal antibody) may be incorporated as part of the conditioning or consolidation strategy to enhance targeting of B-cell lymphomas.
Approved indications
- Relapsed or refractory B-cell non-Hodgkin lymphoma
- Hodgkin lymphoma (as conditioning for autologous transplantation)
Common side effects
- Neutropenia
- Thrombocytopenia
- Mucositis
- Infection
- Nausea and vomiting
- Secondary malignancy
- Graft failure
Key clinical trials
- Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma (PHASE2)
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: